This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Hepatitis Congress Updates

Excellent survival rates reported for long-term entecavir or tenofovir therapy for chronic hepatitis patients

21.02.17

The 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting was held November 11-15 in Boston.

Read more>>